Skip to main content
Top
Published in: Advances in Therapy 9/2019

Open Access 01-09-2019 | Tiotropium | Brief Report

Reduced Environmental Impact of the Reusable Respimat® Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers

Authors: Michaela Hänsel, Thomas Bambach, Herbert Wachtel

Published in: Advances in Therapy | Issue 9/2019

Login to get access

Abstract

Introduction

Pressurised metered-dose inhalers (pMDIs) are associated with global warming potential values as they contain a hydrofluoroalkane (HFA) propellant, whereas the Respimat® Soft Mist™ inhaler is propellant-free. The original disposable Respimat has recently been updated to provide a reusable device that is similar in performance and use but is more convenient to patients and reduces environmental impact. This study compared the product carbon footprint (PCF) of Respimat (both disposable and reusable) and pMDIs to understand life cycle hotspots, and also to determine the potential quantitative environmental benefits of a reusable Respimat product.

Methods

PCFs of four inhalation products—tiotropium bromide (Spiriva®) Respimat, ipratropium bromide/fenoterol hydrobromide (Berodual®) Respimat, Berodual HFA pMDI and ipratropium bromide (Atrovent®) HFA pMDI—were assessed across their whole life cycle.

Results

Data show that Respimat inhalers have a lower PCF (carbon dioxide equivalent per kilogram) than HFA pMDIs: pMDI Atrovent 14.59; pMDI Berodual 16.48; disposable Spiriva Respimat 0.78; disposable Berodual Respimat 0.78. Approximately 98% of the pMDI life cycle total is due to HFA propellant emissions during use and end-of-life phases. The impact of the material used for the Respimat product outweighs the impact of the material used to make the empty cartridge. Furthermore, compared with the single-use device over 1 month, the PCF of Spiriva Respimat was further reduced by 57% and 71% using the device with refill cartridges over 3 and 6 months, respectively.

Conclusion

Together, these data suggest that Respimat inhalers, and in particular the new reusable inhaler, can reduce the environmental impact associated with inhaler use.

Funding

Boehringer Ingelheim.
Footnotes
1
Spiriva® Respimat®: Spiriva (tiotropium bromide) delivered via the Respimat inhaler (both disposable and reusable devices).
 
2
Berodual® Respimat®: Berodual (fenoterol hydrobromide + ipratropium bromide) delivered via the Respimat inhaler.
 
3
Berodual® HFA pMDI: Berodual (fenoterol hydrobromide + ipratropium bromide) delivered via an HFA metered-dose inhaler.
 
4
Atrovent® HFA pMDI: Atrovent (ipratropium bromide) delivered via an HFA metered-dose inhaler.
 
5
The cartridge can be used for 60 actuations (Spiriva® Respimat®) or 120 actuations (Berodual® Respimat), sufficient for 30 days’ use with the standard daily dose of 2 actuations (Spiriva Respimat: 2 actuations = 1 dose once daily) or 4 actuations (Berodual Respimat: 1 actuation = 1 dose 4 times) a day.
 
Literature
1.
go back to reference Wachtel H, Kattenbeck S, Dunne S, Disse B. The Respimat® development story: patient-centered innovation. Pulm Ther. 2017;3:19–30.CrossRef Wachtel H, Kattenbeck S, Dunne S, Disse B. The Respimat® development story: patient-centered innovation. Pulm Ther. 2017;3:19–30.CrossRef
2.
go back to reference Forte R Jr, Dibble C. The role of international environmental agreements in metered-dose inhaler technology changes. J Allergy Clin Immunol. 1999;104:S217–20.CrossRefPubMed Forte R Jr, Dibble C. The role of international environmental agreements in metered-dose inhaler technology changes. J Allergy Clin Immunol. 1999;104:S217–20.CrossRefPubMed
3.
go back to reference Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA–MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3:763–70.CrossRefPubMedPubMedCentral Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA–MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3:763–70.CrossRefPubMedPubMedCentral
Metadata
Title
Reduced Environmental Impact of the Reusable Respimat® Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
Authors
Michaela Hänsel
Thomas Bambach
Herbert Wachtel
Publication date
01-09-2019
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 9/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01028-y

Other articles of this Issue 9/2019

Advances in Therapy 9/2019 Go to the issue